COMPASS Pathways is a publicly listed company (NASDAQ) that aims to develop psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. It has gone public and has received substantial investment from atai.
“COMPASS is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our first programme is researching how psilocybin therapy could help people with treatment-resistant depression.”
COMPASS has received an FDA breakthrough therapy designation which means that the development of psilocybin-assisted therapy is advancing at an accelerated pace. It has completed a Phase IIb study with 233 patients in Europe and North America.
Topics of Interest
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
COMPASS Pathways partners with One Mind to fund Rising Star Awards for the next generation of mental health researchers
(GlobeNewswire, 20 April 2022)
COMPASS Pathways presents the largest ever study of psilocybin therapy, at the American Psychiatric Association annual meeting
(GlobeNewswire, 23 May 2022)
COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults
(GlobeNewswire, 09 May 2022)
Drug companies are investing big in psychedelics, but can they engineer out the trip?
(Chemical & Engineering News, 06 March 2022)
COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression
(GlobeNewswire, 03 May 2022)
New partnership launched with SLaM and COMPASS Pathways
(King's College London, 24 March 2022)
Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?
(Psychedelic Spotlight, 21 April 2022)
The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of
(Motherboard, 24 January 2022)
This article, by the always excellent Shayla Love, discussed the next generation of novel psychedelics. Starting with the many discoveries of Sasha Shulgin, the article then dives deeper into the wishes and hopes of psychedelic companies.
Compass Pathways' Phase IIb psilocybin trial shows reduced depression symptoms
(, 04 October 2022)
Psychedelic companies say Compass study result validates industry's hope to find alternative treatments for mental health
(, 18 November 2021)
COMPASS Pathways granted fifth US patent for crystalline psilocybin
(, 23 November 2021)
atai Life Sciences increases its ownership position in COMPASS Pathways
(, 29 November 2021)
COMPASS Pathways to participate in upcoming Evercore, H.C. Wainwright & Berenberg investor conferences
(, 30 November 2021)
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study
(, 13 December 2021)
COMPASS Selected for Addition to NASDAQ Biotechnology Index
(, 17 December 2021)
Guy Goodwin joins COMPASS Pathways as Chief Medical Officer
(, 04 October 2022)
COMPASS Pathways announces the appointment of eminent psychiatrist, Professor Guy Goodwin, as Chief Medical Officer.
HQ / Office
Fora, 33 Broadwick St, London W1F 0DQ, UK